Abivax’s Obefazimod Shows Promising Safety in Late‑Stage Ulcerative Colitis Maintenance Study

When it comes to chronic inflammatory bowel diseases, patients and doctors alike have been waiting for a therapy that can keep symptoms at bay without the baggage of harsh side effects. This week, French biotech Abivax shared a first look at the safety data from its pivotal phase‑3 trial of obefazimod, a novel oral agent aimed at maintaining remission in ulcerative colitis.

The study, officially called the ABiVAC‑UC‑M trial, enrolled roughly 550 adults who had already responded to induction therapy. Participants were randomised to receive either obefazimod 50 mg once daily or a matching placebo, and they were followed for up to 52 weeks. The primary focus of this interim analysis was safety – essentially, "does the drug cause any new or unexpected problems?" – while secondary endpoints tracked relapse rates and quality‑of‑life measures.

So far, the numbers look reassuring. Adverse events were reported in 48 % of the obefazimod group compared with 45 % of placebo‑treated patients. Most of those were mild or moderate – things like headache, nausea, or a transient rise in liver enzymes that resolved without intervention. Serious adverse events were rare: 4 % of those on obefazimod experienced a serious issue versus 5 % on placebo, and none were judged to be directly linked to the study drug.

What caught the eye of clinicians, though, was the pattern of disease‑related outcomes. While the trial isn’t powered to draw definitive efficacy conclusions yet, early signals suggested that fewer patients on obefazimod experienced a relapse during the first 24 weeks (22 % vs. 31 % on placebo). In other words, the drug may be doing its primary job – keeping the gut calm – while staying largely benign.

Abivax’s CEO, Marc Boffo, reminded investors that safety is a non‑negotiable gate‑keeper for chronic therapies. "Patients with ulcerative colitis need a maintenance option that they can take every day without fearing long‑term toxicity," he said in a webcast. "These interim data give us confidence that obefazimod could fill that space."

Experts not involved in the trial echoed a measured optimism. Dr. Elena Martinez, a gastroenterologist at the University of Chicago, noted, "Oral agents that spare patients from frequent infusions are a welcome addition. If the final efficacy read‑out confirms what we’re seeing now, obefazimod could become a real game‑changer." She did caution that the full dataset, especially the 52‑week safety profile, will be critical before any definitive conclusions can be drawn.

Looking ahead, Abivax plans to release the complete 52‑week safety and efficacy results later this year, with a potential filing for regulatory approval in Europe and the United States soon after. For the roughly 3 million people worldwide living with ulcerative colitis, the prospect of a once‑daily pill that maintains remission without a heavy side‑effect burden is a hopeful glimpse of what could soon become reality.